Pervanadate-triggered MAP kinase activation and cell proliferation are not sensitive to PD 98059 Evidence for stimulus-dependent differential PD 98059 inhibition mechanism by Krady, Marie-Marthe et al.
Pervanadate-triggered MAP kinase activation and cell proliferation are
not sensitive to PD 98059
Evidence for stimulus-dependent di¡erential PD 98059 inhibition mechanism
Marie-Marthe Kradya, Anant N. Malviyaa;*, Jean-Luc Dupontb
aLaboratoire de Neurobiologie MoleŁculaire des Interactions Cellulaires, CNRS UPR 416, 5 rue Blaise Pascal, 67084 Strasbourg, France
bLaboratoire de Neurobiologie Cellulaire, CNRS UPR 9009, 5 rue Blaise Pascal, 67084 Strasbourg, France
Received 21 June 1998
Abstract A tight and stable complex with corresponding
protein kinases and phosphatases establishes coupling between
activators and inactivators. One such example is emerging from
the studies of the Ras-dependent MAP kinase cascade signaling
pathway. Pervanadate, a potent inhibitor of protein tyrosine
phosphatase, stimulates MAP kinase and elicits cell proliferation
in cultured mouse fibroblasts which is insensitive to PD 98059,
the major inhibitor of upstream MEK, whereas serum- or TPA-
triggered proliferation is sensitive to PD 98059. It is suggested
that imbalanced coordination between protein kinase and protein
phosphatase determines the cellular responses such as cell
proliferation. The PD 98059-insensitive cell proliferation upon
protein tyrosine phosphatase inhibition is attributed to a MEK
bypass pathway.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Mitogen-activated protein (MAP) kinases, also known as
extracellular signal-regulated kinases (ERKs), act at the end
of a kinase cascade that is activated in response to extracel-
lular signals via receptor tyrosine kinases [1], including the
tumor promoter [2] 12-O-tetradecanoyl phorbol 13-acetate
(TPA). The MAPK family members are key components of
intracellular signaling cascades, and consist of at least 10
members [3^5]. MAPKK (MEK) is a dual speci¢city kinase
that phosphorylates ERK on a threonine and a tyrosine res-
idue in the catalytic domain. Upon activation, ERK/MAP
translocates into the nucleus where it phosphorylates tran-
scription factors and thereby alters gene transcription patterns
[6,7]. Overactivation of protein kinases can lead to uncon-
trolled cell growth and tumorigenesis. There are a wide variety
of protein phosphatases that keep the kinases in check by
performing the opposite operation, dephosphorylation of the
substrate. Thus, a coordinated action between protein kinases
and protein phosphatases determines cellular responses [8].
For the activation of MAP kinase, phosphorylation on threo-
nine as well as tyrosine residues is a prerequisite, but dephos-
phorylation of either one can render the enzyme inactive.
Pervanadate (a potent inhibitor of tyrosine phosphatases) is
su⁄cient to trigger the activation of Raf, MEK and MAP
kinase [9]. Pervanadate treatment of C3H 10T1/2 mouse ¢bro-
blasts led to proliferation [2]. Pervanadate has also been re-
ported to down-regulate gap junctional communication and
to increase phosphorylation in connexin-43 in studies with
hamster lung ¢broblasts [10]. Some of the signals that activate
MAP kinase are prevented by PD 98059, a compound that
speci¢cally inhibits the activation of MEK [11], the major
upstream activator of MAPK. However, PD 98059-insensitive
phosphorylation of connexin-43 has been reported when per-
vanadate stimulated MAP kinase. In the studies reported
here, we directly examined the e¡ect of PD 98059 on MAP
kinase activation/translocation to the nucleus and the cell pro-
liferation induced by stimulating protein kinase pathway
(treating cells with serum or TPA) or by inhibiting protein
tyrosine phosphatase (treating cells with pervanadate). The
signals activating MAP kinase by inhibiting protein tyrosine
phosphatase were found to be insensitive to PD 98059 which
indicates that an additional mechanism of MAP kinase acti-
vation operates when tyrosine phosphatase is inhibited. These
¢ndings are relevant in view of the physical union of protein
kinases and phosphatases that is considered crucial to guar-
antee ¢delity of signal transduction pathways [8].
2. Materials and methods
2.1. Materials
C3H 10T1/2 embryonic mouse ¢broblasts were obtained from Dr.
C.E. Wenner (Bu¡alo, NY) [Q-32P]ATP and 5-[125I]iodo-2P-deoxy ur-
idine were purchased from Amersham, Anti-ACTIVE MAPK anti-
body was from Promega, anti-ERK-2 antibody was from Santa
Cruz Biotechnology, PD 98059 was from Calbiochem, and all other
reagents of highest purity grade were from Sigma, France. Pervana-
date (phosphotyrosine phosphatase inhibitor) was prepared as de-
scribed [2].
2.2. Cell cultures
C3H 10T1/2 embryonic mouse ¢broblasts [12] were used at passage
15^22 at the post-con£uence quiescent state. Cultures were maintained
in Dulbecco’s modi¢ed Eagle’s medium (DMEM) supplemented with
10% inactivated fetal calf serum in a 5% CO2 atmosphere at 37‡C.
The culture medium was renewed 5 days after plating on Petri dishes
and cells attained con£uence at 9^10 days. Con£uent cells were serum
starved for 48 h and subsequently treated for 20 min with either 10%
serum, TPA (160 nM) or pervanadate (12.5 WM) to activate MAP
kinase.
2.3. Immunohistochemistry
For immunohistochemistry, cultures were treated with stimuli (per-
vanadate, TPA or fetal calf serum) or with the inhibitor (PD 98059).
The primary antibody used in these experiments was the polyclonal
Anti-ACTIVE MAPK antibody raised against the active form of p42/
44 MAP kinase.
After a brief rinse with phosphate-bu¡ered saline (PBS), cells were
¢xed in paraformaldehyde (4% in PBS) for 30 min followed by wash-
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ing three times with PBS. To permeabilize cell membranes, cultures
were immersed 30 min in a 0.2% Triton X-100-supplemented PBS
solution. After three additional rinses with PBS, the cells were incu-
bated for 20 min in 10% normal goat serum in PBS to block non-
speci¢c binding. The cultures were then incubated overnight with the
primary antibody (1/200 dilution) at 4‡C. After three washes in the 5%
goat serum-PBS solution, the cells were incubated for 1 h in a goat
anti-rabbit secondary antibody (Jackson) £uorescein isothiocyanate-
conjugated (1/200 in 5% goat serum-PBS). Cells were washed three
times in PBS and mounted in Vectashield mounting medium (Vector)
to reduce photobleaching. Proper controls were carried out while
omitting the primary antibody in the incubation bath.
2.4. Preparation of nuclear fraction
Post-con£uent cells were deprived of serum for 48 h before stimu-
lation with TPA or pervanadate or serum. Cells were pretreated with
PD 98059 for 90 min as indicated. Following treatment, cells were
rinsed gently three times with a medium containing 20 mM Tris-HCl,
pH 7.5, 1 mM MgCl2 and 1 mM dithiothreitol (medium A). Petri
dishes with attached cells were frozen at 380‡C for 2 h. After thawing
on ice, cells were harvested in medium A, centrifuged at 600Ug for 10
min at 4‡C and the resulting pellet was homogenized in 2 volumes of
medium A supplemented with 1.3 M sucrose. Adequate amounts of
medium A supplemented with 2.4 M sucrose were added to this sus-
pension so as to give a ¢nal concentration of 2.2 M sucrose in the
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Fig. 1. Immunohistochemical detection of MAP kinase activation in C3H 10T1/2 ¢broblasts. A direct visualization of active MAP kinase loca-
tion was achieved using Anti-ACTIVE MAP kinase antibody. Cells were stimulated with 12.5 WM pervanadate (A), 160 nM TPA (C), or 10%
fetal calf serum (E) or were unstimulated, i.e. without any treatment (G). The inhibitory e¡ect of 50 WM PD 98059 was tested on cells stimu-
lated with 12.5 WM pervanadate (B), TPA (D) or serum (F). Control (H) was obtained by omitting the primary antibody from the immunohis-
tochemical staining.
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medium. This was homogenized with up and down strokes in a
Dounce homogenizer and centrifuged at 100 000Ug for 20 min at
4‡C in a Beckman TL 100 ultracentrifuge. The resulting pellet con-
sisted of isolated nuclei which were devoid of any plasma membrane
contaminants as attested by marker enzyme activity [13]. The isolated
nuclei were resuspended in a medium containing 20 mM Tris-HCl, pH
7.5, 4 mM MgCl2, 2 mM EDTA, 10% glycerol, 0.5% Triton X-100, 2
mM phenylmethylsulfonyl £uoride, 2 mM Na3VO4, 20 mM NaF, 10
Wg/ml leupeptin and aprotinin, 25 Wg/ml trypsin inhibitor, sonicated
three times (5 s each) with a 1 min interval between two sonications
and centrifuged at 100 000Ug for 20 min. The supernatant constituted
the nuclear fraction.
2.5. Cellular protein extraction
After treatment with di¡erent stimuli, cells were washed with PBS
and subsequently lysed with an extraction bu¡er (20 mM L-glycerol-
phosphate pH 7.5, 2 mM EDTA, 1 mM DTT, 2 mM MgCl2, 10%
glycerol, 0.1% Triton X-100, 20 mM NaF, 2 mM phenylmethylsul-
fonyl £uoride, 2 mM Na3VO4, 10 Wg/ml leupeptin, sonicated four
times (5 s each) on ice with a 1 min interval between sonications.
The lysate was clari¢ed by centrifugation at 12 000Ug for 10 min.
2.6. MAP kinase activity
The kinase assay medium contained: 20 mM HEPES, pH 7.5, 20
mM L-glycerophosphate, pH 7.5, 20 mM NaF, 2 mM EDTA, 2 mM
Na3VO4, 10 mM MgCl2, 100 WM ATP, 0.28 mg/ml myelin basic
protein (MBP) and 3^5U105 cpm [Q32-P]ATP. An appropriate
amount of cellular fractions was assayed for MAP kinase activity.
After incubation (15 min at 30‡C), labelled MBP was precipitated
by TCA (20%) and the 32P incorporated into MBP was determined
by Cerenkov spectrometry. The protein in each fraction was deter-
mined by the Bradford procedure [14] using the Bio-Rad protein assay
dye reagent.
2.7. Western blotting
Nuclear fractions were mixed with electrophoresis sample bu¡er
and boiled for 5 min at 90‡C. Proteins were separated on SDS-
PAGE (10% acrylamide). After electrophoresis, proteins were trans-
ferred to nitrocellulose membrane using a Bio-Rad semi-dry appara-
tus. The immunoblot was revealed using anti-ERK-2 antibody
(1:1000 dilution), or Anti-ACTIVE MAPK antibody (1:20 000 dilu-
tion) as primary antibody, employing alkaline phosphatase-conju-
gated secondary antibody. The immunoblot was developed using
NBT-BCIP reagent.
2.8. Cell proliferation
For the 125I-labeled uridine incorporation assay, cells were plated in
24-well plates (Falcon, Oxnard, CA) at a density of 1.6U106 cells per
well. The DNA synthesis as well as the number of cells were counted
employing trypan blue staining as described [2].
3. Results
Employing Anti-ACTIVE MAP kinase antibody revealed
immunolabeling of nuclei upon treatment of cells in culture
with pervanadate, serum or TPA (Fig. 1). The labeling was
more intense when cells were treated with pervanadate (Fig.
1A) as compared with TPA (Fig. 1C) or serum (Fig. 1E)
treatment. Preincubating cells with the medium supplemented
with PD 98059 followed by pervanadate stimulation did not
change the £uorescence (Fig. 1B), whereas weak £uorescence
was seen with TPA (Fig. 1D) or serum (Fig. 1F) treatment. In
unstimulated cells (Fig. 1G) no active MAP kinase nuclear
labeling was seen. Immunocytochemical data were fully sup-
ported by Western blot analysis of the nuclear fractions ob-
tained from cells variously stimulated. PD 98059 insensitivity
was seen when signals activating MAP kinase were derived
from pervanadate treatment (Fig. 2) while TPA- or serum-
mediated MAP kinase activation was sensitive to PD 98059.
It may be noted here, consistent with the current notion, that
pervanadate was the most potent stimulus of MAP kinase
activation (Fig. 3). The proliferation was studied by determin-
ing DNA synthesis (Fig. 4A) and cell counts (Fig. 4B). The
degree of proliferation due to pervanadate treatment of cells
ran parallel to MAP kinase activation. Pervanadate-mediated
cell proliferation was not sensitive to PD 98059 (Fig. 4B).
4. Discussion
Cellular responses to external signals require coordinated
control of protein kinases and protein phosphatases. Thus a
picture is emerging where multiple complexes containing both
kinases and phosphatases [15,16] are strong candidates for the
regulation and speci¢city of signaling pathways. Any process
that imbalances such a ¢ne coordination results in an over-
activated cellular response. In this scenario pervanadate, a
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Fig. 2. Western blotting of nuclear fractions. Nuclear fractions (A,
B) were separated on SDS-PAGE and transferred to nitrocellulose
membrane. The nitrocellulose membranes were subjected to Western
blotting using Anti-ACTIVE MAPK antibodies (A) or anti-Erk2
antibodies (B). Lane 1, untreated cell ; lane 2, 12.5 WM pervanadate
(20 min); lane 3, 160 nM TPA (30 min); lane 4, 10% serum; lane
5, cells treated with 50 WM PD 98059 and 12.5 WM pervanadate;
lane 6, cells treated with 50 WM PD 98059 and 160 nM TPA; lane
7, cells treated with PD 98059 and 10% serum. 20 Wg protein was
loaded on each lane in A and 30 Wg in B.
Fig. 3. E¡ect of PD 98059 on p42/44 MAP kinase activity. MAP
kinase activity was determined in whole cell lysate after pretreat-
ment with or without 50 WM PD 98059 for 90 min followed by
stimulation with 10% serum, 12.5 WM pervanadate or 160 nM TPA
for 20 min.
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potent inhibitor of protein tyrosine phosphatase, has been
recognized as a powerful activator of the Ras-Raf-MAP kin-
ase cascade. Phosphorylation of Stat proteins in the nucleus
[17], overphosphorylation of connexin-43 [18] and prolifera-
tion of C3H 10T1/2 mouse ¢broblasts [2] are some of the
examples of pervanadate-mediated preferred signal activation
as contrasted to signals generated due to the classical protein
kinase activation mechanism.
Against this background we investigated the role of PD
98059 in inactivating MAP kinase and cell proliferation trig-
gered by pervanadate with due comparison to similar e¡ects
elicited by serum or TPA treatment of cultured mouse ¢bro-
blasts. PD 98059 inhibited MAP kinase activation/transloca-
tion to the nucleus and proliferation induced by serum or
TPA. It may be recalled here that both serum and TPA act
via the Ras-dependent protein kinase cascade and PD 98059
inhibits MEK, the upstream activator of MAP kinase. And
therefore the action of PD 98059 in rendering MAP kinase
inactive is expected. In addition we report here that PD 98059
treatment of cells in culture abrogates serum- or TPA-trig-
gered proliferation. Thus a direct action of PD 98059 on re-
versal of TPA- or serum-mediated proliferation is observed.
Our results are in complete agreement with the PD 98059-
sensitive proliferation mediated by PDGF [19] or leptin [20].
Yet another important message that has emerged from
these studies concerns PD 98059-insensitive MAP kinase acti-
vation and cell proliferation. Interestingly, pervanadate-trig-
gered MAP kinase action (proliferation as well) has not been
found to be sensitive to PD 98059. This clearly demonstrates
that the stable complex between MEK and its phosphatase is
destabilized due to inhibition of tyrosine phosphatase and this
imbalance causes overstimulation of downstream MAP kinase
in a PD 98059-insensitive manner. Alternatively, inhibition of
dual speci¢city MAP kinase phosphatase [21] targeting ERK
by pervanadate keeps ERK (42/44 kinase as seen here) acti-
vated even when cells are inhibited by PD 98059. And there-
fore for cell proliferation, ERK activation is crucial and that
is why PD 98059 is not able to reverse proliferation elicited by
pervanadate. The selectivity of dual speci¢city phosphatase
MKP-3 in tight binding to ERKs and not other MAP kinase
family members such as JNK/SAPKs or p38 is well estab-
lished [16].
In summary, these observations clearly demonstrate that
the PD 98059-insensitive pathway operates in cellular re-
sponses such as cell proliferation (at least in mouse ¢bro-
blasts) and MAP kinase activation/translocation to the nu-
cleus. In this context pervanadate has emerged as a major
tool for understanding the tight association of protein kinases
and protein phosphatases.
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Fig. 4. E¡ect of PD 98059 on cell proliferation. A: DNA synthesis
was determined by [125I]deoxyuridine incorporation. PD 98059 (50
WM) was added in the incubation medium of C3H 10T1/2 cells for
90 min before treatment with pervanadate, TPA or serum. F, 12.5
WM pervanadate; E, 50 WM PD+12.5 WM pervanadate; R 160 nM
TPA; j, 50 WM PD+160 nM TPA; b, 10% serum; a, 50 WM
PD+10% serum; U, untreated cells. B: The numbers of C3H
10T1/2 cells were counted after 40 h of incubation with or without
PD 98059 (50 WM) pretreatment followed by di¡erent e¡ector treat-
ments.
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